Teva Pharmaceutical Industries Ltd Archives

Home / Posts tagged Teva Pharmaceutical Industries Ltd

Teva Launches Rise: A Global Open Innovation Platform to Accelerate AI, Industry 4.0, Smart Manufacturing, Digital Health and Biotech Breakthroughs for Pharma’s Biggest Challenges

First cohort features 7 real-world challenges across R&D, manufacturing and supply chain, commercial and medical affairs Teva’s first-ever global innovation platform aims to accelerate patient impact and drive business transformation, as part of its Pivot to Growth Strategy Rise will enable startups and tech players worldwide to validate their solutions in real-world settings, scaling impact [...]

AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living

In a new cohort of 27 adults from the IMPACT-TD Registry, up to 77% of participants reported improvements in aspects of their lives impacted by tardive dyskinesia (TD) while taking AUSTEDO or AUSTEDO XR Most (85%) participants taking AUSTEDO or AUSTEDO XR in conjunction with their mental health medications reported that their mental health condition [...]

Teva’s Innovative Portfolio Drives 11th Consecutive Quarter of Growth in Q3 2025; Increases 2025 Outlook for Austedo® and Non-GAAP EPS

For an accessible version of this Press Release, please visit www.tevapharm.com Teva reports revenues of $4.5 billion in the third quarter of 2025, an increase of 3% year-over-year (YoY) in U.S. dollars or 1% in local currency (LC). Excluding Japan BV in Q3 2024, revenues increased 5% in U.S. dollars or 3% in LC. United [...]

Teva to Present at UBS Global Healthcare Conference and Jefferies London Healthcare Conference in November

TEL AVIV, Israel, Oct. 31, 2025 (Korea Bizwire) – Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva’s President and CEO, will present at two upcoming investor conferences in November as follows: UBS Global Healthcare Conference Monday, November 10, 2025, at 8:45 A.M. Eastern Time (ET) Jefferies London Healthcare Conference Tuesday, [...]

Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5, 2025

TEL AVIV, Israel, Sept. 25, 2025 (Korea Bizwire) – Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its third quarter 2025 financial results on Wednesday, November 5, 2025, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on [...]

Patients Taking AUSTEDO XR® (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction

Of the 209 patients with tardive dyskinesia (TD) that were surveyed, >94% reported movement improvement once treated with AUSTEDO XR® (deutetrabenazine) extended-release tablets Patients reported high satisfaction (>89%) with AUSTEDO XR, with 96% expressing interest in continuing treatment Almost all (>96%) patients relayed that AUSTEDO XR was easy to take PARSIPPANY, N.J. and TEL AVIV, Israel, [...]

Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting

TEL AVIV, Israel, Sept. 16, 2025 (Korea Bizwire) – Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced plans to present data from the completed phase 3 SOLARIS trial at the 2025 Psych Congress Annual Meeting, taking place from September 17 – 21, 2025, in San Diego, California. Teva will also host a conference [...]

Teva’s Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System Atrophy

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a different kind of global biopharmaceutical leader, one that operates across the full spectrum of innovation to reliably deliver medicines to patients worldwide. (Image from Teva webpage) Teva received Fast Track designation from the U.S. Food and Drug Administration for emrusolmin (TEV-56286), an investigational treatment for [...]

Teva to Present at Morgan Stanley Global Healthcare Conference and Bank of America Global Healthcare Conference in September

TEL AVIV, Israel, Sept. 02, 2025 (Korea Bizwire) – Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva’s President and CEO, will present at two upcoming investor conferences in September as follows: Morgan Stanley 23rd Annual Global Healthcare Conference Tuesday, September 9, 2025, at 8:30 A.M. ET BofA Global Healthcare [...]

Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss

Generic Saxenda® is the first-ever generic GLP-1 indicated for weight loss, addressing increased demand for this category of therapies in the U.S. market. This approval and launch add to Teva’s continued commitment to its complex generic medicine portfolio as part of its Pivot to Growth Strategy. Liraglutide injection is indicated for adults with obesity or overweight [...]